Treating ocular toxoplasmosis: current evidence

Stanford, Miles; Gilbert, Ruth

doi:10.1590/s0074-02762009000200027

Cited by 38 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[15][16][17] Accumulating evidences indicate that vaccination with stage-specific antigens leads to stage-limited protection against T. gondii. 3,18 Therefore, developing multiantigenic DNA vaccine in connection with the different life stages of the parasite may conquer the deficiency of using a single antigen. 19,20 In the present study, we constructed DNA vaccines expressing the ROP16/ GRA7 antigens (pROP16, pGRA7, and pROP16-GRA7), and a plasmid encoding murine costimulatory molecule B7-2 (pB7-2) as a genetic adjuvant.…”

Section: Cd8mentioning

confidence: 99%

See 1 more Smart Citation

Toxoplasma gondii

Liu

Wang

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Cd8mentioning

confidence: 99%

“…2 Treatment of toxoplasmosis is difficult since the available drugs frequently cause adverse effects. 3 Under the present scenario, developing an effective vaccine against T. gondii would be of great value for controlling and preventing toxoplasmosis.…”

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii

Liu

Wang

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…An evidence-based systematic review disclosed that there is a lack of evidence to support routine antibiotic treatment for acute toxoplasmic retinochoroiditis. 18,19 The ideal drug for ocular toxoplasmosis must be parasitocidal, destroying cysts, reaching optimal concentrations in the posterior segment, and having an acceptable tolerance profile. None of the current available drugs fulfill all these criteria.…”

Section: Treatmentmentioning

confidence: 99%

Toxoplasmosis: new challenges for an old disease

Bodaghi

Fardeau

Paris

et al. 2012

Eye

View full text Add to dashboard Cite

More than a century after the identification of Toxoplasma gondii, major issues need to be addressed for the optimal management of ocular disease. Toxoplasmic retinochoroiditis is the main cause of posterior uveitis in several geographical areas. The parasite establishes a love-hate relationship with the eye, manipulating the immune response and inducing variable initial lesions and further relapses. It is now well established that most cases are acquired after birth and not congenital. The severity of the disease is mainly due to the parasite genotype and the host immune status. Diagnosis is based on clinical features, but may be confirmed by biological tools applied to ocular fluids. Combining several techniques improves the diagnostic yield in equivocal cases. Therapeutic management is the most important challenge. Even though evidencebased data on the efficacy of anti-parasitic drugs are still missing, new strategies with a good safety profile are available and may be proposed earlier during the course of the disease, but also in selected cases, to reduce sight-threatening relapses. Revisiting the therapeutic options and indications may be an important step towards long-term maintenance of the visual function and avoidance of major complications.

show abstract

“…There is no real consensus on the treatment of retinochoroiditis [72][73][74][75]. Some experts will treat only patients in which the lesions are near the macula or the optic nerve and when there is an important hyalitis with an impairment of the optical acuity.…”

Section: Efficient Treatments Are Available But There Is No Real Meanmentioning

confidence: 99%

“…Other experts will treat all the lesions whatever their localizations and this is now possible because the recommended association pyrimethamine/azythromycine is better tolerated and has a better compliance than pyrimethamine associated to sulfadiazine [76,77]. Corticosteroids (prednisone at 0.5 to 1mg/kg/d) are constantly administered for several weeks, except for immunocompromised patients [73,78]. Pyrimethamine in adults is used at 100mg/d for several days then decreased at 50mg/d.…”

Section: Efficient Treatments Are Available But There Is No Real Meanmentioning

confidence: 99%